secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001661181-26-000007
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis Q1 revenue $36.3M (-58% YoY); net loss $53.2M; FY guidance lowered
--------------------------------------------------------------------------------

- Net revenue $36.3M, down 58% YoY from $86.7M; Advanced Wound Care down 63% to $29.5M.
- Net loss $53.2M ($0.44/sh) vs $18.8M loss ($0.17/sh) in Q1 2025; adjusted net loss $43.7M.
- Adjusted EBITDA loss $48.2M vs $12.5M loss; gross margin collapsed to 29% from 73%.
- FY2026 revenue guidance $270M-$310M, decline of 45%-52% from $564.2M in 2025.
- Cash $92.1M, no debt; expects sequential improvement in Q2 and strong H2 growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000166118126000007/0001661181-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000166118126000007/orgo-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001661181-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer